erlotinib hydrochloride has been researched along with Hand Dermatosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Descourt, R; Misery, L; Roguedas, AM; Rouxel, AM | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Kenner-Bell, BM; Lacouture, ME; Paller, AS | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
4 other study(ies) available for erlotinib hydrochloride and Hand Dermatosis
| Article | Year |
|---|---|
[Hand-foot syndrome: A new side effect of erlotinib].
Topics: Aged; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Erythema; Foot Dermatoses; Foot Diseases; Hand Dermatoses; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Syndrome | 2008 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Epidermal growth factor receptor inhibition with erlotinib for palmoplantar keratoderma.
Topics: Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Protein Kinase Inhibitors; Quinazolines | 2010 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |